Credit Suisse Group set a GBX 6,350 ($82.97) price target on AstraZeneca (LON:AZN) in a research report released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on AZN. Kepler Capital Markets set a GBX 5,630 ($73.57) price objective on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, August 1st. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Thursday. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, October 30th. UBS Group set a GBX 5,900 ($77.09) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Thursday. Finally, Cfra set a GBX 6,200 ($81.01) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Friday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. AstraZeneca currently has an average rating of Hold and an average target price of GBX 5,831.89 ($76.20).
AstraZeneca stock traded up GBX 79 ($1.03) during mid-day trading on Friday, reaching GBX 6,172 ($80.65). 2,861,442 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.